On Monday, the FDA approved guselkumab (Tremfya; Johnson & Johnson) for the treatment of children 6 and older who also weigh at least 40 kg with plaque psoriasis (PsO) and active psoriatic arthritis ...
Larimar Therapeutics (LRMR) announced 25 mg and 50 mg data from the ongoing long-term open label study evaluating daily subcutaneous injections of ...
Helius Medical Technologies, Inc. (NASDAQ: HSDT) has filed a 510(k) submission with the U.S. Food and Drug Administration seeking to expand the label of its Portable Neuromodulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback